Support Alert

Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety alert advising to monitor glucose levels closely in patients with diabetes during direct-acting antiviral therapy for hepatitis C, particularly within the first 3 months of treatment, and modify diabetes medication or doses when necessary.

 

Further details and advice for healthcare professionals can be found on the MHRA website.


Loading...

Email newsletter

Want the latest pharmacy news and updates straight to your inbox?

Sign up to our regular newsletter for the latest guidance, news, events and CPD opportunities.

Sign Up